Biotech Companies Attempting to Save Lives
8:30 am ET October 23, 2017 (PR Newswire) Print
Companies in the biotechnology arena are in business to save lives. Such audacious goals come with lots of risk in the stock market, but if successful, even more reward. In the biotech industry, companies can spend hundreds of millions of dollars and in the end have nothing to show for it. Additionally, Biotech relies on scientific research and data, from this research these companies patent their technologies, and products. A few biotechnology companies to compare and contrast include: Endonovo Therapeutics (OTCQB: ENDV), Pulse Biosciences, Inc. (NASDAQ: PLSE), TherapeuticsMD, Inc. (NASDAQ: TXMD), Genocea Biosciences, Inc. (NASDAQ: GNCA), and Exelixis, Inc. (NASDAQ: EXEL).
Endonovo Therapeutics (OTCQB: ENDV) Market Cap: $18.244M, current share price: $.059
Just last week, ENDV announced the completion of a study evaluating the effectiveness of its lead platform with positive results. After their success in the completed pre-clinical trial, its apparent ENDV is leading the way in biotechnology and electroceuticals. Their lead platform, Immunotronics(TM), is a non-invasive electroceutical, and the pre-clinical study measured evaluated it against in a well-established preclinical model of heart failure (post-MI remodeling). This model used Immunotronics(TM) one, two or three times per day and discovered it drastically increased significantly improved cardiac function and reduced ventricular remodeling, including significant improvements in ejection fraction (EF), fractional shortening (FS) and Left Ventricle Developed Pressure (LVDP), as well as Heart-Weight-to-Body-Weight ratio (HW/BW), which is an index for cardiac hypertrophy (enlarged heart). With its recent success, ENDV plans to continue the development of its pipeline of non-invasive electroceuticals. The completion of this study is a milestone for the electroceutical field and places ENDV as a leader in developing non-invasive therapies for patients with life-threatening inflammatory conditions in vital organs and vascular disease.
8:30 am ET October 23, 2017 (PR Newswire) Print
Companies in the biotechnology arena are in business to save lives. Such audacious goals come with lots of risk in the stock market, but if successful, even more reward. In the biotech industry, companies can spend hundreds of millions of dollars and in the end have nothing to show for it. Additionally, Biotech relies on scientific research and data, from this research these companies patent their technologies, and products. A few biotechnology companies to compare and contrast include: Endonovo Therapeutics (OTCQB: ENDV), Pulse Biosciences, Inc. (NASDAQ: PLSE), TherapeuticsMD, Inc. (NASDAQ: TXMD), Genocea Biosciences, Inc. (NASDAQ: GNCA), and Exelixis, Inc. (NASDAQ: EXEL).
Endonovo Therapeutics (OTCQB: ENDV) Market Cap: $18.244M, current share price: $.059
Just last week, ENDV announced the completion of a study evaluating the effectiveness of its lead platform with positive results. After their success in the completed pre-clinical trial, its apparent ENDV is leading the way in biotechnology and electroceuticals. Their lead platform, Immunotronics(TM), is a non-invasive electroceutical, and the pre-clinical study measured evaluated it against in a well-established preclinical model of heart failure (post-MI remodeling). This model used Immunotronics(TM) one, two or three times per day and discovered it drastically increased significantly improved cardiac function and reduced ventricular remodeling, including significant improvements in ejection fraction (EF), fractional shortening (FS) and Left Ventricle Developed Pressure (LVDP), as well as Heart-Weight-to-Body-Weight ratio (HW/BW), which is an index for cardiac hypertrophy (enlarged heart). With its recent success, ENDV plans to continue the development of its pipeline of non-invasive electroceuticals. The completion of this study is a milestone for the electroceutical field and places ENDV as a leader in developing non-invasive therapies for patients with life-threatening inflammatory conditions in vital organs and vascular disease.
